Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pain 14Multiple Myeloma 12Pain, Postoperative 10Neoplasms 9Agnosia 8Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Cancer Pain 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma 4Leukemia 4Hodgkin Disease 4Head and Neck Neoplasms 4Burkitt Lymphoma 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Hairy Cell 3Hematologic Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Trigger Finger Disorder 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, Mantle-Cell 2

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Lutetium 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Acetaminophen × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡